RT Journal Article
SR Electronic
T1 Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.29.21264272
DO 10.1101/2021.09.29.21264272
A1 Paredes, Miguel I.
A1 Lunn, Stephanie M.
A1 Famulare, Michael
A1 Frisbie, Lauren A.
A1 Painter, Ian
A1 Burstein, Roy
A1 Roychoudhury, Pavitra
A1 Xie, Hong
A1 Bakhash, Shah A. Mohamed
A1 Perez, Ricardo
A1 Lukes, Maria
A1 Ellis, Sean
A1 Sathees, Saraswathi
A1 Mathias, Patrick C.
A1 Greninger, Alexander
A1 Starita, Lea M.
A1 Frazar, Chris D.
A1 Ryke, Erica
A1 Zhong, Weizhi
A1 Gamboa, Luis
A1 Threlkeld, Machiko
A1 Lee, Jover
A1 McDermot, Evan
A1 Truong, Melissa
A1 Nickerson, Deborah A.
A1 Bates, Daniel L.
A1 Hartman, Matthew E.
A1 Haugen, Eric
A1 Nguyen, Truong N.
A1 Richards, Joshua D.
A1 Rodriguez, Jacob L.
A1 Stamatoyannopoulos, John A.
A1 Thorland, Eric
A1 Melly, Geoff
A1 Dykema, Philip E.
A1 MacKellar, Drew C.
A1 Gray, Hannah K.
A1 Singh, Avi
A1 Peterson, JohnAric M.
A1 Russell, Denny
A1 Torres, Laura Marcela
A1 Lindquist, Scott
A1 Bedford, Trevor
A1 Allen, Krisandra J.
A1 Oltean, Hanna N.
YR 2022
UL http://medrxiv.org/content/early/2022/02/16/2021.09.29.21264272.abstract
AB Background The COVID-19 pandemic is dominated by variant viruses; the resulting impact on disease severity remains unclear. Using a retrospective cohort study, we assessed the hospitalization risk following infection with seven SARS-CoV-2 variants.Methods Our study includes individuals with positive SARS-CoV-2 RT-PCR in the Washington Disease Reporting System with available viral genome data, from December 1, 2020 to January 14, 2022. The analysis was restricted to cases with specimens collected through sentinel surveillance. Using a Cox proportional hazards model with mixed effects, we estimated hazard ratios (HR) for hospitalization risk following infection with a variant, adjusting for age, sex, calendar week, and vaccination.Findings 58,848 cases were sequenced through sentinel surveillance, of which 1705 (2.9%) were hospitalized due to COVID-19. Higher hospitalization risk was found for infections with Gamma (HR 3.20, 95%CI 2.40-4.26), Beta (HR 2.85, 95%CI 1.56-5.23), Delta (HR 2.28 95%CI 1.56-3.34) or Alpha (HR 1.64, 95%CI 1.29-2.07) compared to infections with ancestral lineages; Omicron (HR 0.92, 95%CI 0.56-1.52) showed no significant difference in risk. Following Alpha, Gamma, or Delta infection, unvaccinated patients show higher hospitalization risk, while vaccinated patients show no significant difference in risk, both compared to unvaccinated, ancestral lineage cases. Hospitalization risk following Omicron infection is lower with vaccination.Conclusion Infection with Alpha, Gamma, or Delta results in a higher hospitalization risk, with vaccination attenuating that risk. Our findings support hospital preparedness, vaccination, and genomic surveillance.Summary Hospitalization risk following infection with SARS-CoV-2 variant remains unclear. We find a higher hospitalization risk in cases infected with Alpha, Beta, Gamma, and Delta, but not Omicron, with vaccination lowering risk. Our findings support hospital preparedness, vaccination, and genomic surveillance.Competing Interest StatementALG reports central testing lab from Abbott and research funding from Merck and Gilead. KA became an employee of Biobot Analytics after the initial manuscript submission. All other authors declare no competing interestsFunding StatementT.B. is a Pew Biomedical Scholar and a Howard Hughes Medical Institute Investigator and is supported by NIH grant no. R35 GM119774. P.R. is supported by a CFAR New Investigator Award (NIH AI027757). The Seattle Flu Study is run through the Brotman Baty Institute for Precision Medicine and funded by Gates Ventures, the private office of Bill Gates. This work was supported by CDC BAA contract 75D30121C10982. Employees of the Institute for Disease Modeling (MF, RB) received no specific funding for the project. Computational analyses for UW Virology data were supported by Fred Hutch Scientific Computing (NIH ORIP grant S10OD028685).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Washington State Institutional Review Board designated this study as exempt. Sequencing and analysis of samples from the Seattle Flu Study was approved by the Institutional Review Board (IRB) at the University of Washington (protocol STUDY00006181). Sequencing of remnant clinical specimens at UW Virology Lab was approved by the University of Washington Institutional Review Board (protocol STUDY00000408). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests to access these data are handled by the Washington Department of Health